Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc.DNA · Entity 5530 | Director · See remarks | July 28, 2026 | July 30, 2026 |
| SomaLogic, Inc.CMII · Entity 95310 | Director | February 22, 2021 | February 22, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ginkgo Bioworks Holdings, Inc.
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 74,258 |
Reported balance
After 2026-07-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 74,258 · Balance 74,258 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 309,467 |
Reported balance
After 2026-07-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-28 · Grant · Acquired 309,467 · Balance 309,467 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest as follows: 75% on October 16, 2026 and 25% on January 21, 2027.
F3: The RSUs were approved by the Compensation Committee of the Board of Directors on July 28, 2026 and shall vest in equal quarterly installments over the next 12 quarters, with the first vesting to occur on October 16, 2026.
SomaLogic, Inc.
Report date February 22, 2021 · Filed February 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-02-22 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-252626) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-252626) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 09, 2023 Filed Aug 11, 2023 21:02 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.04 | $203,800.00 |
DisclosureSEC source: 0001127602-23-022386 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,994,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.985 to $2.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.04 | $204,300.00 |
DisclosureSEC source: 0001127602-23-022030 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,094,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 21:01 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.07 | $206,900.00 |
DisclosureSEC source: 0001127602-23-022030 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,194,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 21:04 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.35 | $235,300.00 |
DisclosureSEC source: 0001127602-23-021533 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,294,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.235 to $2.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 26, 2023 Filed Jul 28, 2023 21:04 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.38 | $238,300.00 |
DisclosureSEC source: 0001127602-23-021533 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,394,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.285 to $2.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 20:54 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.29 | $228,600.00 |
DisclosureSEC source: 0001127602-23-021155 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,494,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.215 to $2.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 20:54 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.47 | $247,300.00 |
DisclosureSEC source: 0001127602-23-021155 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,594,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.37 to $2.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 13, 2023 Filed Jul 14, 2023 20:50 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.23 | $222,500.00 |
DisclosureSEC source: 0001127602-23-020733 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,694,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.14 to $2.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 12, 2023 Filed Jul 14, 2023 20:50 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $2.09 | $209,200.00 |
DisclosureSEC source: 0001127602-23-020733 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,794,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.005 to $2.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 20:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.72 | $172,100.00 |
DisclosureSEC source: 0001127602-23-020472 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,894,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.68 to $1.785, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:55 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.81 | $181,300.00 |
DisclosureSEC source: 0001127602-23-020472 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,994,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 20:49 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.81 | $181,300.00 |
DisclosureSEC source: 0001127602-23-019640 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,094,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.77 to $1.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 20:49 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.70 | $169,500.00 |
DisclosureSEC source: 0001127602-23-019640 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,194,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.59 to $1.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 20:46 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.70 | $170,300.00 |
DisclosureSEC source: 0001127602-23-019334 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,294,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.65 to $1.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:46 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.79 | $179,200.00 |
DisclosureSEC source: 0001127602-23-019334 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,394,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 22:28 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.93 | $193,000.00 |
DisclosureSEC source: 0001127602-23-018910 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,494,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 22:28 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.95 | $195,000.00 |
DisclosureSEC source: 0001127602-23-018910 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,594,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $2.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 08, 2023 Filed Jun 9, 2023 21:11 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.74 | $173,700.00 |
DisclosureSEC source: 0001127602-23-018446 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,694,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.685 to $1.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 21:11 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.80 | $179,500.00 |
DisclosureSEC source: 0001127602-23-018446 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,794,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.745 to $1.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 21:05 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.68 | $168,000.00 |
DisclosureSEC source: 0001127602-23-017597 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,894,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.58 to $1.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 21:05 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.59 | $159,000.00 |
DisclosureSEC source: 0001127602-23-017597 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,994,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.55 to $1.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 25, 2023 Filed May 26, 2023 21:03 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.52 | $152,300.00 |
DisclosureSEC source: 0001127602-23-016981 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,094,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.485 to $1.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:03 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.56 | $155,800.00 |
DisclosureSEC source: 0001127602-23-016981 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,194,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.475 to $1.625, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:53 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.30 | $130,200.00 |
DisclosureSEC source: 0001127602-23-016332 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,294,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.265 to $1.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:53 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.26 | $125,500.00 |
DisclosureSEC source: 0001127602-23-016332 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,394,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.20 to $1.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 11, 2023 Filed May 12, 2023 21:04 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.32 | $132,100.00 |
DisclosureSEC source: 0001127602-23-015472 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,494,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.255 to $1.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 10, 2023 Filed May 12, 2023 21:04 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.35 | $135,100.00 |
DisclosureSEC source: 0001127602-23-015472 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,594,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.28 to $1.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 04, 2023 Filed May 5, 2023 21:19 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.19 | $119,100.00 |
DisclosureSEC source: 0001127602-23-014765 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,694,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.215, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 03, 2023 Filed May 5, 2023 21:19 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.17 | $116,600.00 |
DisclosureSEC source: 0001127602-23-014765 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,794,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.125 to $1.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 20:46 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.18 | $118,200.00 |
DisclosureSEC source: 0001127602-23-013796 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,894,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.16 to $1.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:46 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.19 | $119,300.00 |
DisclosureSEC source: 0001127602-23-013796 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,994,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.17 to $1.235, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 20, 2023 Filed Apr 21, 2023 20:46 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.28 | $128,400.00 |
DisclosureSEC source: 0001127602-23-013363 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,094,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.26 to $1.325, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 20:46 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.30 | $130,300.00 |
DisclosureSEC source: 0001127602-23-013363 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,194,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.235 to $1.355, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 13, 2023 Filed Apr 14, 2023 20:54 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.33 | $132,500.00 |
DisclosureSEC source: 0001127602-23-012938 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,294,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.295 to $1.345, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:54 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.31 | $131,000.00 |
DisclosureSEC source: 0001127602-23-012938 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,394,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.27 to $1.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 06, 2023 Filed Apr 7, 2023 20:53 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.31 | $131,000.00 |
DisclosureSEC source: 0001127602-23-012727 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,494,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.21 to $1.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 20:53 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.22 | $121,600.00 |
DisclosureSEC source: 0001127602-23-012727 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,594,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.19 to $1.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 30, 2023 Filed Mar 31, 2023 21:32 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.24 | $124,400.00 |
DisclosureSEC source: 0001127602-23-011721 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,694,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.22 to $1.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 21:32 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.24 | $123,500.00 |
DisclosureSEC source: 0001127602-23-011721 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,794,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.205 to $1.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 23, 2023 Filed Mar 24, 2023 21:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.26 | $125,800.00 |
DisclosureSEC source: 0001127602-23-011325 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,894,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.20 to $1.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 22, 2023 Filed Mar 24, 2023 21:16 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.29 | $128,500.00 |
DisclosureSEC source: 0001127602-23-011325 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,994,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.22 to $1.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 21:02 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.32 | $131,500.00 |
DisclosureSEC source: 0001127602-23-010721 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,094,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.26 to $1.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 21:02 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.32 | $131,700.00 |
DisclosureSEC source: 0001127602-23-010721 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,194,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.28 to $1.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 21:29 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 300,000 | $1.33 | $399,000.00 |
DisclosureSEC source: 0001127602-23-010467 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,294,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.290 to $1.395, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:26 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.39 | $139,400.00 |
DisclosureSEC source: 0001127602-23-008818 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,594,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.33 to $1.475, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 23, 2023 Filed Feb 24, 2023 22:14 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.61 | $160,500.00 |
DisclosureSEC source: 0001127602-23-007100 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,694,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.54 to $1.725, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:14 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.65 | $164,700.00 |
DisclosureSEC source: 0001127602-23-007100 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,794,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.585 to $1.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 22:11 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.77 | $177,300.00 |
DisclosureSEC source: 0001127602-23-005898 · form4.xml · nonDerivative · entry 2 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,894,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.715 to $1.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:11 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.79 | $179,100.00 |
DisclosureSEC source: 0001127602-23-005898 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,994,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.705 to $1.845, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 21:45 UTC | Ginkgo Bioworks Holdings, Inc. DNA · Entity 5530 | SaleClass A Common Stock | 100,000 | $1.81 | $181,300.00 |
DisclosureSEC source: 0001127602-23-004493 · form4.xml · nonDerivative · entry 1 Kelly Jason R · CIK 0001845677 · Director · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,094,680 F1 · kind: The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.74 to $1.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.